NanoMedSyn
Pre-clinicalNanoMedSyn develops AMFA glycoligands that leverage the M6PR pathway to enable precise, targeted delivery for next‑generation therapeutics
Founded
2013
Focus
Small Molecules
About
NanoMedSyn develops AMFA glycoligands that leverage the M6PR pathway to enable precise, targeted delivery for next‑generation therapeutics
Company Info
TypePrivate
Founded2013
LocationMontpellier, France
StagePre-clinical
Contact
SIMILAR COMPANIES
4P-Pharma
Phase 2 · Lille
Patheon
Pre-clinical · Lyon
ABL Diagnostics
Pre-clinical · Strasbourg
Acticor Biotech
Pre-clinical · Paris
Adjuvatis
Pre-clinical · Lyon
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile